B-Raf Kinase V600E oncogenic mutant in complex with PLX7922

Summary for 4XV3

Related4K04 4K0I 4K1A
DescriptorSerine/threonine-protein kinase B-raf, N'-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-N-ethyl-N-methylsulfuric diamide (3 entities in total)
Functional Keywordsb-raf, braf, proto-oncogene, v600e, kinase, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (Human)
Cellular locationNucleus  P15056
Total number of polymer chains2
Total molecular weight67050.85
Zhang, Y.,Zhang, C. (deposition date: 2015-01-26, release date: 2015-10-28, Last modification date: 2015-11-04)
Primary citation
Zhang, C.,Spevak, W.,Zhang, Y.,Burton, E.A.,Ma, Y.,Habets, G.,Zhang, J.,Lin, J.,Ewing, T.,Matusow, B.,Tsang, G.,Marimuthu, A.,Cho, H.,Wu, G.,Wang, W.,Fong, D.,Nguyen, H.,Shi, S.,Womack, P.,Nespi, M.,Shellooe, R.,Carias, H.,Powell, B.,Light, E.,Sanftner, L.,Walters, J.,Tsai, J.,West, B.L.,Visor, G.,Rezaei, H.,Lin, P.S.,Nolop, K.,Ibrahim, P.N.,Hirth, P.,Bollag, G.
RAF inhibitors that evade paradoxical MAPK pathway activation.
Nature, 526:583-586, 2015
PubMed: 26466569 (PDB entries with the same primary citation)
DOI: 10.1038/nature14982
MImport into Mendeley
Experimental method

Structure validation

RfreeClashscoreRamachandran outliersSidechain outliersRSRZ outliers0.28660.4%2.1%3.1%MetricValuePercentile RanksWorseBetterPercentile relative to all X-ray structuresPercentile relative to X-ray structures of similar resolution
Download full validation report